All the news

Providing hepatitis B treatment for everyone who needs it in Malawi is an achievable public health goal, researchers from the Malawi-Liverpool-Wellcome Trust programme report, following community surveys in Blantyre, Malawi. Hepatitis B treatment ...

People with HIV and hepatitis B co-infection remain at risk for developing hepatocellular carcinoma (HCC) despite antiviral treatment and should undergo regular monitoring for liver cancer, according to research presented ...

Testing for chronic hepatitis B infection was very low in people living with HIV in Cameroon, a country with a high burden of hepatitis B, and suppression of hepatitis B virus was ...

People with HIV and hepatitis B virus (HBV) co-infection have more than double the risk of death if they have ongoing high-level HBV replication, indicating a need for prompt treatment, according to an ...

HIV-positive people with hepatitis B virus (HBV) co-infection had impaired CD4 cell recovery after starting antiretroviral therapy (ART) and a higher risk of death than those without hepatitis B, but use of ...

Tenofovir, which has potent activity against both HIV and hepatitis B virus (HBV), is the most effective hepatitis B treatment for people with HIV and HBV co-infection, according to a 23-study meta-analysis ...

A study involving people co-infected with HIV and hepatitis B virus (HBV) shows that antiretroviral therapy that combines tenofovir with FTC or 3TC has the best chance of suppressing HBV replication to undetectable ...

People with HIV and hepatitis B virus (HBV) co-infection, who substituted tenofovir (Viread) for zidovudine (Retrovir) or abacavir (Ziagen) in their antiretroviral regimen, saw a reduction in hepatitis B viral load despite HBV ...

Liver-related outcomes are poorer in HIV-positive patients who are co-infected with hepatitis B virus genotype B compared to co-infected patients with hepatitis B genotype C, Taiwanese investigators report in the online edition of ...